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Abstract:  Hereditary  hemochromatosis  (HH)  is  an  autosomal  recessive  disorder 
characterized  by  enhanced  intestinal  absorption  of  dietary  iron.  Without  therapeutic 
intervention,  iron  overload  leads  to  multiple  organ  damage  such  as  liver  
cirrhosis, cardiomyopathy, diabetes, arthritis, hypogonadism and skin pigmentation. Most 
HH  patients  carry  HFE  mutant  genotypes:  homozygosity  for  p.Cys282Tyr  or 
p.Cys282Tyr/p.His63Asp compound heterozygosity. In addition to HFE gene, mutations in 
the genes that encode hemojuvelin (HJV), hepcidin (HAMP), transferrin receptor 2 (TFR2) 
and ferroportin (SLC40A1) have been associated with regulation of iron homeostasis and 
development  of  HH.  The  aim  of  this  review  was  to  identify  the  main  gene  mutations 
involved in the pathogenesis of type 1, 2, 3 and 4 HH and their genetic testing indication. 
HFE  testing  for  the  two  main  mutations  (p.Cys282Tyr  and  p.His63Asp)  should  be 
performed in all patients with primary iron overload and unexplained increased transferrin 
saturation and/or serum ferritin values. The evaluation of the HJV p.Gly320Val mutation 
must be the molecular test of choice in suspected patients with juvenile hemochromatosis 
with less than 30 years and cardiac or endocrine manifestations. In conclusion, HH is an 
example that genetic testing can, in addition to performing the differential diagnostic with 
secondary iron overload, lead to more adequate and faster treatment. 
Keywords: hemochromatosis; primary iron overload; HFE; high-resolution melting; HJV; 
molecular diagnostic 
 
OPEN ACCESS Int. J. Mol. Sci. 2012, 13   
 
1498 
1. Introduction 
Hereditary hemochromatosis (HH) is an autosomal recessive disorder characterized by enhanced 
intestinal absorption of dietary iron. Without therapeutic intervention, iron overload leads to multiple 
organ  damage  such  as  liver  cirrhosis,  cardiomyopathy,  diabetes,  arthritis,  hypogonadism  and  skin 
pigmentation. However, iron can be efficiently and safely removed by therapeutic phlebotomy, which 
is initiated by withdrawing blood at a rate of 500 mL per week until serum ferritin reaches <50 µ g/L. 
The  oral  iron  chelator  deferasirox  is  not  registered  for  genetic  iron  overload,  since  conventional 
phlebotomies have much lower side effects. But recent studies reported that oral chelator could be used 
in exceptional cases [1–5]. 
The major mutation that has been associated with disease is the p.Cys282Tyr in the HFE gene that 
occurs in approximately 80% of HH cases. In addition, a high proportion of the remaining patients are 
compound heterozygous for the HFE p.Cys282Tyr and the common HFE p.His63Asp alteration [6–8]. 
In Northern European populations, the HFE p.Cys282Tyr homozygous genotype is particularly common 
(1 in 200–300 healthy subjects) and the HFE 282Tyr allele frequency is high (5.1 to 8.2%) [9]. In 
contrast, in countries with racial/ethnic heterogeneity from South America, Asia and Africa a lower 
prevalence of HH have been observed, and an increased number of patients with primary iron overload 
do not carry the p.Cys282Tyr/p.Cys282Tyr or p.Cys282Tyr/p.His63Asp genotypes [10,11] (for example, 
a minor allele frequency of p.Cys282Tyr allele of 2.3% is observed in Brazilian blood donors) [12,13].  
In  addition to  the  HFE  gene,  mutations in the genes that encode hemojuvelin (HJV),  hepcidin 
(HAMP), transferrin receptor 2 (TFR2) and ferroportin (SLC40A1) have been associated with regulation 
of iron homeostasis and development of HH [9,14,15]. 
Early diagnostic and initiation of iron-depletion therapy ensure life quality and increase survival 
times of HH patients. In this scenario, genetic testing applied to HH can, in addition to performing the 
differential diagnostic with secondary iron overload, lead to more adequate and faster treatment. Thus, 
the pivotal aim of this review was to identify the main gene mutations involved in the pathogenesis of 
the type 1, 2, 3 and 4 HH and their genetic testing indications. 
2. HH Types, Related Genes and Their Main Mutations 
According to OMIM (Online Mendelian Inheritance in Man, www.ncbi.nlm.nih.gov/omin) 5 types 
of HH have been identified on the basis of clinical, biochemical, and genetic characteristics (Table 1). 
The  classic  hemochromatosis  is  most  often  caused  by  a  mutation  in  a  gene  designated  HFE  on 
chromosome 6p21.3. Nonetheless, in minor frequency, there are 4 additional disorders of primary iron 
overload: juvenile hemochromatosis (JH) or type 2 hemochromatosis, which is divided into 2 forms: 
type 2A JH, caused by mutations in the HJV gene on chromosome 1q21, and type 2B JH, caused by 
mutations in the HAMP gene on chromosome 19q13. HH types 3 and 4 are caused by mutations in the 
TFR2 and SLC40A1 genes on chromosomes 7q22 and 2q32, respectively (Table 1) [16–19]. 
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Table 1. Characteristics according to HH types. 
HH 
types 
Phenotype 
MIM 
number 
Gene 
MIM 
number 
Location  Inheritance  Gene product function 
Main clinical 
manifestations 
1  235200 
HFE, 
613609 
6p21.3  AR 
Involved in hepcidin 
synthesis via BMP6, 
interaction with TFR1. 
Arthropathy, skin 
pigmentation, liver 
damage, diabetes, 
endocrine dysfunction, 
cardiomyopathy, 
hypogonadism. 
2A  602390 
HJV, 
608374 
1p21  AR 
Involved in hepcidin 
synthesis, BMP  
co-receptor. 
Types 2: earlier onset, 
<30 years old. 
Hypogonadism and 
cardiomyopathy more 
prevalent. 
2B  613313 
HAMP, 
606464 
19q13  AR 
Downregulation of iron 
efflux from enterocytes. 
3  604250 
TFR2, 
604720 
7q22  AR 
Involved in hepcidin 
synthesis, interaction with 
transferrin. 
As for type 1. 
4  606069 
SLC40A1, 
604653 
2q32  AD  Duodenal iron export. 
Lower tolerance to 
phlebotomies and may 
have anemia. 
MIM:  Mendelian  Inheritance  in  Man;  TFR1:  transferrin  receptor  1,  HFE:  encodes  HFE  protein;  HJV: 
encodes hemojuvelin; HAMP: encodes hepcidin; TFR2: encodes transferrin receptor 2; SLC40A1: encodes 
ferroportin;  BMP6:  bone  morphogenetic  protein  6,  AR:  autosomal  recessive;  AD:  autosomal  dominant.  
 
2.1. HFE 
HFE related-HH (OMIM 235200), classified as type 1, is the most frequent form of the disease and 
the most common autosomal recessive disorder in Northern European populations. HH is characterized 
by  enhanced  intestinal  absorption  of  iron  leading  to  multiple  organ  damage,  such  as  cirrhosis, 
hepatoma, diabetes mellitus, arthritis, cardiomyopathy, and hypogonadism [20–23]. 
HFE gene (613609), constituted by 6 exons, encodes a membrane protein that is similar to major 
histocompatibility class I-like proteins, called HFE. 
Most HH patients  carry homozygosity  for p.Cys282Tyr or  p.Cys282Tyr/p.His63Asp compound 
heterozygous genotypes. Besides the missense mutation at position 282, where cysteine is replaced by 
tyrosine (p.Cys282Tyr, c.845G>A, rs1800562) and the common substitution of histidine for aspartic 
acid at position 63 (p.His63Asp, c.187C>G, rs1799945), a third mutation is also commonly assessed: 
the substitution of cysteine for serine at amino acid position 65 (p.Ser65Cys, c.193A>T, rs1800730). 
However, recent reports have suggested that rare  HFE variants, such as p.Gly43Ala, p.Leu46Trp, 
p.Val53Met,  p.Gly93Arg,  p.Ile105Thr,  p.Gln127His,  p.Asp129Asn,  p.Glu168Gln,  p.Glu168del, 
p.Leu183Pro,  p.Glu277Lys,  p.Gln283Pro,  p.Val284Met,  p.Arg330Met,  and  a  deletion  in  the  6p 
chromosome region containing  HFE  could also be  linked to  HH thus  contributing to  genetic  and 
phenotypic heterogeneity of the disease [6,7,9,15,24,25]. 
The first proposed pathogenic mechanism for explaining HH was the disruption of a disulfide bond 
in HFE that is critical for its binding to β2 microglobulin. This complex interacts with transferrin 
receptor 1, decreasing the affinity with transferrin and consequently modulating iron absorption in Int. J. Mol. Sci. 2012, 13   
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enterocytes [26]. However, in recent years, evidences indicating HFE protein as a hepcidin modulator 
have emerged. The functional loss of HFE in mice and humans has been shown to reduce hepcidin 
synthesis [27–29] and that HFE loss seems to be associated with blunted signaling responses to BMP6 
(bone morphogenetic protein 6), a key regulator of hepcidin, in vitro and in vivo [30,31]. Indeed, HFE 
related-HH has been associated with reduced hepcidin levels (Figure 1) [24,28,29]. 
Figure 1. Normal (A) and hemochromatosis (B) conditions. A1: HFE, HJV, and TFR2 
modulates hepcidin synthesis by hepatocytes; A2: normal hepcidin levels; A3: hepcidin-
ferroportin interaction with internalization and ferroportin degradation in enterocytes; A4: 
normal iron absorption. B1: HFE or HJV or TFR2 gene mutations alter hepcidin synthesis 
modulation; B2: lower hepcidin levels; B3: decreased hepcidin-ferroportin interaction and 
increased  ferroportin  activity;  B4:  iron  overload  observed  in  types  1,  2  and  3 
hemochromatosis. TFR2: transferrin receptor 2; TFR1: transferrin receptor 1, HFE: HFE 
protein; HJV: hemojuvelin. 
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2.2. HJV and HAMP 
Juvenile hemochromatosis (JH), also classified as type 2, is a rare autosomal recessive disorder  
of  iron  overload  that  leads  to  organ  damage  before  the  age  of  30,  and  usually  causes  
cardiomyopathy, hypogonadotrophic hypogonadism, liver damages and endocrine dysfunctions. Types 
2A (OMIM 602390) and 2B (OMIM 613313) are caused by mutations in HJV and HAMP genes, 
respectively [32,33].  
HJV (608374) gene, constituted by 4 exons, was identified in 2004 and encodes a protein called 
hemojuvelin [32]. Patients with type 2A JH and knockout mice models demonstrate low hepcidin 
levels implying that hemojuvelin is involved in the hepcidin synthesis [34]. HAMP gene (606464), 
constituted by 3 exons, encodes hepcidin, a peptide known as iron hormone. Hepcidin is produced  
by  hepatocytes  and  it  plays  a  role  in  iron  absorption  related  to  ferroportin  degradation  of  the 
enterocytes [33,35]. 
Several  HJV  mutations  have  been  found  in  patients:  p.Arg54del,  p.Cys80Arg,  p.Ser85Pro, 
p.Gly99Arg,  p.Gly99Val,  p.Leu101Pro,  p.Gly116del,  p.Cys119Phe,  p.Ile222Asn,  p.Arg131fs, 
p.Asp149fs,  p.Leu165del,  p.Ala168Asp,  p.Phe170Ser,  p.Asp172Glu,  p.Arg176Cys,  p.Trp191Cys, 
p.Asn196Lys,  p.Ser205Arg,  p.Ile222Asn,  p.Lys234del,  p.Asp249His,  p.Gly250Val,  p.Asn269fs, 
p.Ile281Thr,  p.Arg288Trp,  p.Cys321Trp,  p.Cys321del,  p.Arg326del,  p.Ser328fs,  p.Cys361fs,  and 
p.Arg385del. However, the HJV p.Gly320Val is the most frequent mutation and has been reported in 
JH patients in several populations around the world [22,32,36–39]. In contrast, mutations in HAMP are 
a very rare cause of JH: p.Met31fs, p.Met50fs, p.Arg56del, p.Arg59Gly, p.Cys70Arg, p.Gly71Asp, 
and p.Cys78Thr [22,33,40,41]. In addition, some studies support the concept that digenic inheritance 
of HFE and HJV or of HFE and HAMP mutations can lead to iron overload or may aggravate the 
phenotype [37,39,41–44]. 
For both type 2A and 2B JH, it is well established that the cause of iron overload may be explained 
by  decreases  in  the  synthesis  and,  consequently  depressed  hepcidin  levels  (Figure  1)  [34,45].  
Cell-surface expression of hemojuvelin was associated with increased expression of hepcidin; likewise, 
loss of hemojuvelin expression, as in juvenile hemochromatosis, was associated with reduced hepcidin 
expression [22,46]. 
HJV seems to play a role in iron absorption and release from cells and has anti-inflammatory 
properties [47]. An important study revealed that HJV acts as a BMP co-receptor and signals via the 
SMAD pathway to regulate hepcidin expression [46,48]. A BMP6 dependent signaling pathway has 
been shown to play a key role in regulation of hepcidin expression [24]. BMPs bind to type I and type 
II  serine  threonine  kinase  receptors,  which  phosphorylate  specific  intracellular  SMAD  proteins 
(SMAD1,5,8). Phosphorylated SMAD1,5,8 (P-SMAD1,5,8) binds to the common mediator SMAD4, 
and  the SMAD complex translocates to  the nucleus  to affect transcription of target genes  HAMP 
(encoding hepcidin) is transcriptionally up-regulated by BMPs [46,49–52]. Impaired hepatic signaling 
through mutations in genes encoding either the ligand BMP6, the BMP coreceptor hemojuvelin or 
Smad4 leads to low hepcidin levels and iron overload in mice. Collectively, these data show that  
BMP-SMAD  signaling  is  an  important  regulatory  pathway  for  hepcidin  expression  and  thus  iron 
metabolism [53–56]. Int. J. Mol. Sci. 2012, 13   
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2.3. TFR2 
Type 3 HH (OMIM 604250) is an autosomal recessive disease caused by mutations in TFR2 gene 
and iron overload is similar to HFE related-HH phenotype. TFR2 gene (604720), constituted by 18 
exons, encodes transferrin receptor 2 protein (TFR2). TFR2 is involved with uptake of transferrin 
bound iron by hepatocytes and it is also involved in the hepcidin synthesis [57–60]. One possibility is 
that it operates in the pathway discussed above for HFE (or in a parallel pathway of its own) facilitating 
the BMP/SMAD signaling that activates hepcidin expression. Another possibility is that TFR2, which 
is also able to interact with HFE, forms an iron-sensing complex that modulates hepcidin expression in 
response to blood levels of diferric transferrin [24,61–63]. 
This disorder seems to be rare and few TFR2 mutations have been reported: p.His33Asn, p.Glu60del, 
p.Arg105del,  p.Met172Lys,  p.Tyr250del,  p.Gln317del,  p.Arg396del,  p.Ala444Thr,  p.Arg455Gln, 
p.Arg481His, p.Leu490Arg, p.Val561del, p.Gln690Pro, and p.Gly792Arg. In both animal models and 
patients with TFR2 related-HH decreased hepcidin levels were observed (Figure 1) [22,42,57,64–67]. 
2.4. SLC40A1 
Type 4 HH (OMIM 606069) has an autosomal dominant pattern and it is caused by mutations in the 
SLC40A1 gene. This rare disease can present peculiar clinical features such as high serum ferritin 
levels plus low or normal transferrin saturation values until the end stage of the disease. It may also be 
the presence of a mild iron-deficient anemia in the initial stage and a reduced tolerance to therapeutic 
phlebotomy [45,68,69]. 
SLC40A1 (604353) gene, constituted by 8 exons, encodes a membrane transporter called ferroportin 
that modulates iron efflux [70]. SLC40A1 mutations, such as p.His32Arg, p.Tyr64Asn, p.Val72Asp, 
p.Ala77Asp,  p.Gly80Val,  p.Arg88Thr,  p.Asn144His,  p.Asp157Gly,  p.Asp157Asn,  p.Val162del, 
p.Asn174Ile,  p.Arg178Gly,  p.Ile180Thr,  p.Asp181Val,  p.Gln182His,  p.Asn185Asp,  p.Gln248His, 
p.Gly267Asp,  p.Gly323Val,  p.Cys326Ser,  p.Cys326Tyr,  p.Gly330del,  p.Ser338Arg,  p.Arg489Ser, 
p.Gly490Asp, and p.Gly490Val were associated with type 4 HH. Two hypotheses have been proposed 
to account for this disease: the trapping of iron in macrophages that are unable to export iron and the 
failure to be degraded by interaction with hepcidin [22,42,69–74]. 
3. Biochemical Assays for Body Iron Store Analysis 
The most common biochemical assays performed in laboratorial routine for iron overload analysis 
are serum iron, TIBC (total iron binding capacity), transferrin saturation (TS, which is a ratio between 
serum iron and TIBC expressed as percentage), and serum ferritin. Serum ferritin is a highly sensitive 
test for iron overload in HH, but it has low specificity, being also elevated in inflammatory process, 
diabetes, alcohol consumption, and liver damage.  
Usually, TS values can be a helpful tool as a marker of iron overload. Some studies reported that TS 
values are usually higher than 50% in females and 60% in males with iron overload caused by genetic 
alterations  [16,75–77].  In  addition,  a  scale  has  been  proposed  by  the  Haute  Autorité   de  Santé   as 
clinical  recommendations  on  the  HH  management:  stage  0:  without  biochemical  and  clinical 
abnormalities; stage 1: increased TS (>45%), normal serum ferritin, and no clinical symptoms; stage 2: Int. J. Mol. Sci. 2012, 13   
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increased TS, increased serum ferritin (>200 µ g/L in females and >300 µ g/L in males), but no clinical 
symptoms;  stage  3:  abnormal  biochemical  values  and  initial  clinical  symptoms  (fatigue,  arthritis, 
impotence, skin hyperpigmentation); and stage 4: abnormal biochemical values, and clinical symptoms 
manifesting organ damage (cirrhosis, diabetes, hypogonadism, or cardiomyopathy) [76,78]. 
In this context, patients with suspect iron overload should primarily be evaluated through fasting TS 
and serum ferritin. HFE mutations molecular assay should be performed only in those with increased 
biochemical values [79].  
4. Genetic Testing and Methodology 
4.1. Genetic Testing 
HFE testing for the two main mutations (p.Cys282Tyr and p.His63Asp) should be performed in all 
patients with unexplained increased TS and/or serum ferritin values (Figure 2). In these cases, the 
molecular diagnostic of HFE related-HH is usually associated with the presence of the p.Cys282Tyr 
homozygosity and p.Cys282Tyr/p.His63Asp compound heterozygous genotypes. However, p.His63Asp 
homozygous  and  p.His63Asp/p.Ser65Cys  compound  heterozygous  genotypes  have  been  associated 
with HH phenotype [3,15,23]. 
Figure  2.  Representation  of  diagnostic  strategy  for  patients  suspected  hereditary 
hemochromatosis (HH). * Recommendations report TS > 45%, SF > 200 µ g/L in females and > 
300 µ g/L in males; or in advanced stages: TS > 50% in females and TS > 60% in males, in the 
absence of secondary causes [79,80]. ** Some patients with primary iron overload may not present 
mutation during this genetic approach. Very rare mutations in other genes can be involved [15,81]. 
Abbreviations:  TS:  transferrin  saturation;  SF:  serum  ferritin;  JH:  juveline  hemochromatosis.  + 
means positive result, and − means negative result. 
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In the absence of the mentioned HFE genotype combinations, other HH types could be considered. 
When there is genetic iron overload in a patient with less than 30 years and cardiac or endocrine 
manifestations,  JH  diagnostic  is  suggestive  (Figure  2).  Thus,  the  evaluation  of  the  p.Gly320Val 
mutation in the HJV gene must be the molecular test of choice. According to several studies, this 
procedure would confirm the majority of JH cases [5,29]. Early diagnosis is paramount. If result is 
negative, sequencing should be performed to evaluate the HJV and HAMP genes (Figure 2). Our group 
reported  a  case  with  both  clinical  and  molecular  diagnostic  of  JH,  and  the  use  of  deferasirox  
therapy adjunct to  venesections  during the initial treatment  presented significant  improvements  as 
cardiomyopathy and liver disease were prevented, and endocrine functions were normalized [5].  
Mutations in the TFR2 and SLC40A1 genes are rare compared with HFE mutations and they have 
also been reported in children, adolescents, and adults. These genes should be sequenced after negative 
results for other genes (Figure 2). Nowadays, the costs for sequencing have come down, especially if it 
evaluates the number of bases per dollar of the next generation sequencings. However, for the most 
part  of  clinical  practice  around  the  world,  screening  of  HFE,  HJV,  HAMP,  TFR2  and  SLC40A1 
through direct sequencing is not widely available. This approach  is usually reserved for scientific 
studies and for very specific cases such as patients who are not responsive to treatment and had more 
severe complications due to iron overload. In addition and for the most part of cases, the treatment  
is  not  dependent  on  molecular  diagnosis.  Our  group  reported  that  direct  sequencing  does  not 
significantly  improve  the  diagnostic  throughput  as  when  it  was  compared  to  the  sole  HFE  main 
mutations testing [15,19,79,80]. 
4.2. Methodology 
Genotyping of HFE p.Cys282Tyr and p.His63Asp mutations is one of the most requested molecular 
assays in the laboratorial routine. The analysis of single nucleotide polymorphisms, for example HFE 
p.Cys282Tyr,  HFE  p.His63Asp,  and  HJV  p.Gly320Val,  can  be  performed  by  several  available 
methods  for  genotyping  (Figure  2),  such  as  restriction  fragment  length  polymorphisms  (RFLP),  
allele-specific  amplification  analysis  real  time-polymerase,  denaturing  HPLC,  sequencing  strategies, 
TaqMan assay, multiplex amplification followed by reverse hybridization [79,82–84]. A high-resolution-
melting (HRM) assay was developed by our group for genotyping HFE p.Cys282Tyr and p.His63Asp 
mutations in a unique procedure being capable of ensuring the result in approximately 112 minutes and, 
with  cost-effectiveness  especially  in  a  large-scale  demand,  compared  to  methods  cited  above.  The 
advantages of genotyping with this procedure were the non-dependence on gel electrophoresis and on 
mutagenic reagents for visualization of fragments, and the reduction of the chances for contamination 
due to sample preparation compared to RFLP and sequencing strategies. There are disadvantages for 
the  HRM  method:  interference  from  another  genetic  variant  that  may  be  present  in  the  amplicon 
leading to misdiagnosis by altering the curve pattern of the target-mutation. The amplicon for the HFE 
p.Cys282Tyr mutation may present the following known genetic variants: p.Thr281Thr, p.Gln283Pro, 
p.Val284Met; and the amplicon for the HFE p.His63Asp mutation may present the p.Ser65Cys known 
genetic variants. Moreover, non-described mutations may also be present [83,85,86]. Int. J. Mol. Sci. 2012, 13   
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5. Conclusions 
Advances in the understanding of HH have been obtained over the years: association of the HFE 
p.Cys282Tyr  as  the  main  mutation  involved,  genetic  markers  for  juvenile  hemochromatosis  and 
several  pathogenic  mutations  associated  with  non-HFE  HH,  hepcidin  as  an  iron  hormone,  new 
techniques  for  the  laboratorial  evaluation,  and  increased  knowledge  about  HH  management. 
Nonetheless, there are still unclear points to be explored in the HH context: the exact role of the HFE 
protein, molecular pathways of the hepcidin synthesis, the identification of non-genetic factors that 
affect  penetrance,  more  robust  functional  prediction  tools,  and  protein  functionality  assays  more 
informative and easier for the study of identified genetic alterations. 
HFE testing for the two main mutations (p.Cys282Tyr and p.His63Asp) should be performed in all 
suspected patients with primary iron overload and unexplained increased TS and/or serum ferritin 
values. The evaluation of the HJV p.Gly320Val mutation must be the molecular test of choice in 
suspected patients with juvenile hemochromatosis. 
In conclusion, hereditary hemochromatosis is an example that genetic testing can, in addition to 
performing  the  differential  diagnostic  with  secondary  iron  overload,  lead  to  more  adequate  and  
faster treatment. 
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